Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference
08 3월 2022 - 8:30PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that Giuseppe Ciaramella, Ph.D., president and chief
scientific officer, will participate in a fireside chat during the
Barclays 2022 Global Healthcare Conference on Tuesday, March 15,
2022 at 8:30 a.m. ET. The conference will be held in Miami, FL from
March 15-17, 2022.
A live webcast will be available in the investor
section of the company's website at www.beamtx.com, and will be
archived for 60 days following the presentation.
About Beam TherapeuticsBeam
Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to
establishing the leading, fully integrated platform for precision
genetic medicines. To achieve this vision, Beam has assembled a
platform that includes a suite of gene editing and delivery
technologies and is in the process of building internal
manufacturing capabilities. Beam’s suite of gene editing
technologies is anchored by base editing, a proprietary technology
that enables precise, predictable and efficient single base
changes, at targeted genomic sequences, without making
double-stranded breaks in the DNA. This enables a wide range of
potential therapeutic editing strategies that Beam is using to
advance a diversified portfolio of base editing programs. Beam is a
values-driven organization committed to its people, cutting-edge
science, and a vision of providing life-long cures to patients
suffering from serious diseases.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024